Patents by Inventor Eve Laure Mathieu

Eve Laure Mathieu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF BIOMARKERS FOR DETECTING AND EVALUATING A HEPATIC FIBROSIS
    Publication number: 20220205039
    Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
    Type: Application
    Filed: December 28, 2021
    Publication date: June 30, 2022
    Inventors: BÉNÉDICTE WATELET, TARIK ASSELAH, IVAN BIECHE, ISABELLE CATHERINE BATXELLI, NATHALIE JULLIAN, MICHEL VIDAUD, PATRICK MARCELLIN, DANIEL LAUNE, MOHAMMAD AFSHAR, EVE LAURE MATHIEU
  • COMBINATION OF BIOMARKERS FOR DETECTING AND EVALUATING A HEPATIC FIBROSIS
    Publication number: 20200056235
    Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
    Type: Application
    Filed: August 28, 2019
    Publication date: February 20, 2020
    Inventors: BÉNÉDICTE WATELET, TARIK ASSELAH, IVAN BIECHE, ISABELLE CATHERINE BATXELLI, NATHALIE JULLIAN, MICHEL VIDAUD, PATRICK MARCELLIN, DANIEL LAUNE, MOHAMMAD AFSHAR, EVE LAURE MATHIEU
  • Combination of biomarkers for detecting and evaluating a hepatic fibrosis
    Patent number: 10435744
    Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: October 8, 2019
    Assignees: BIO-RAD EUROPE GMBH, ARIANA PHARMACEUTICALS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Bénédicte Watelet, Tarik Asselah, Ivan Bieche, Isabelle Catherine Batxelli, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Daniel Laune, Mohammad Afshar, Eve Laure Mathieu
  • Combination of biomarkers for the prognosis of response or non-response to an anti-HCV treatment
    Patent number: 9879320
    Abstract: The application concerns means for predicting whether a subject infected with one or more HCVs has a high probability of responding to an anti-HCV treatment which will comprise the administration of interferon and of ribavirin or whether, in contrast, that subject has a high probability of not responding to that anti-HCV treatment. The means of the invention in particular involve assaying the levels of expression of selected genes, said selected genes being: at least one gene from among MBL2, LGALS3BP and IL8, and at least one gene from among G1P2, CCL21 and CXCL10, and optionally, at least one gene from among AFP, CRP, CXCL11, CXCL6, CXCL9, FGF7, MDK, MMP2, SFN, TGFB2 and VEGFD.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: January 30, 2018
    Inventors: Ivan Bieche, Bénédicte Watelet, Tarik Asselah, Isabelle Catherine Batxelli, Eve Laure Mathieu, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Mohammad Afshar
  • COMBINATION OF BIOMARKERS FOR DETECTING AND EVALUATING A HEPATIC FIBROSIS
    Publication number: 20170283871
    Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
    Type: Application
    Filed: April 17, 2017
    Publication date: October 5, 2017
    Inventors: BÉNÉDICTE WATELET, TARIK ASSELAH, IVAN BIECHE, ISABELLE CATHERINE BATXELLI, NATHALIE JULLIAN, MICHEL VIDAUD, PATRICK MARCELLIN, DANIEL LAUNE, MOHAMMAD AFSHAR, EVE LAURE MATHIEU
  • Combination of biomarkers for the detection and evaluation of hepatitis fibrosis
    Patent number: 9624541
    Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: April 18, 2017
    Assignees: BIO-RAD INNOVATIONS, ARIANA PHARMACEUTICALS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Bénédicte Watelet, Tarik Asselah, Ivan Bieche, Isabelle Catherine Batxelli, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Daniel Laune, Mohammad Afshar, Eve Laure Mathieu
  • COMBINATION OF BIOMARKERS FOR THE DETECTION AND EVALUATION OF HEPATITIS FIBROSIS
    Publication number: 20130323720
    Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.
    Type: Application
    Filed: February 9, 2012
    Publication date: December 5, 2013
    Applicant: BIO RAD INNOVATIONS
    Inventors: Bénédicte Watelet, Tarik Asselah, Ivan Bieche, Isabelle Catherine Batxelli, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Daniel Laune, Mohammad Afshar, Eve Laure Mathieu
  • COMBINATION OF BIOMARKERS FOR THE PROGNOSIS OF RESPONSE OR NON-RESPONSE TO AN ANTI-HCV TREATMENT
    Publication number: 20130316332
    Abstract: The application concerns means for predicting whether a subject infected with one or more HCVs has a high probability of responding to an anti-HCV treatment which will comprise the administration of interferon and of ribavirin or whether, in contrast, that subject has a high probability of not responding to that anti-HCV treatment. The means of the invention in particular involve assaying the levels of expression of selected genes, said selected genes being: at least one gene from among MBL2, LGALS3BP and IL8, and at least one gene from among G1P2, CCL21 and CXCL10, and optionally, at least one gene from among AFP, CRP, CXCL11, CXCL6, CXCL9, FGF7, MDK, MMP2, SFN, TGFB2 and VEGFD.
    Type: Application
    Filed: February 9, 2012
    Publication date: November 28, 2013
    Applicants: BIO-RAD INNOVATIONS, ARIANA PHARMACEUTICALS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Ivan Bieche, Bénédicte Watelet, Tarik Asselah, Isabelle Catherine Batxelli, Eve Laure Mathieu, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Mohammad Afshar